Table 2.
Virus | Design | Responses | References |
---|---|---|---|
Influenza virus | Immunodominant epitopes | Immunodominant CD4(+)/CD8(+) T‐cell responses | 97, 98 |
Recombinant PIV5 encoding NC | Humoral and T‐cell responses | 96 | |
HIV | Zinc inhibitors | Strong antiviral ability but quite toxic | 99 |
Noncovalent NC inhibitors | Great specificity and less toxic | 99, 100, 101, 102, 103, 104, 105 | |
SARS‐CoV | DNA vaccine expressing NC fusing with calreticulin | B‐cell and T‐cell and specific humoral response | 106 |
DNA vaccine of NC fused with lysosome‐associated membrane protein | Long‐lasting T‐cell memory response | 107 | |
DNA vaccine plasmids expressing NC and IL‐12 | IL‐12 plays an immunoadjuvant and better specific humoral and cellular immunity | 108 | |
Immunodominant epitopes | B‐cell and T‐cell responses | 109, 110 | |
Expressing from Lactobacillus lactis | Significant NC‐specific IgG in the sera | 111 | |
Expressing in tobacco | Strong humoral and cellular responses | 112 |
HIV, human immunodeficiency virus; IL‐12, interleukin‐12; NCs, nucleocapsid proteins; PIV5, parainfluenza virus 5; SARS, severe acute respiratory syndrome coronavirus.